Indian drugmaker Aurobindo Pharma reported a 33% rise in second-quarter profit to $118.89 million, driven by strong US demand and acquisitions. Revenue grew 24%, supported by 10 new drug launches and
reuters · 2026-11-04 07:27
Indian markets anticipate gains as US-Iran diplomatic progress lowers oil prices, alongside key industrial updates including Aurobindo Pharma's acquisition and a safety incident at BCL Industries' eth
reuters · 2026-06-21 19:28
Indian stocks declined amid US-Iran tensions and elevated oil prices. Industry highlights include Aurobindo Pharma's new biologics facility and BHEL securing a Dangote petrochemical contract.
reuters · 2026-06-03 19:35